Search results for "Elea"

showing 10 items of 772 documents

Gonadotropin-releasing hormone (GnRH)-I regulation of interleukin (IL)-1b and IL-1 receptor antagonist expression in cultured human endometrial strom…

2008

Aim:  Human endometrium is an active site of cytokine production and action. Among these cytokines, the interleukin-1 (IL-1) system seems to be relevant to the embryonic implantation process. We have previously reported the production of GnRH-I by human blastocyst, as well as the presence of GnRH-I receptor in human endometrium. This suggests a close interaction between the immune and endocrine systems through these cytokine mediators in embryonic implantation. Methods:  To test the relevance of this interaction during embryonic implantation, we investigated GnRH-I regulation of IL-1b and IL-1ra mRNA and protein expression in human endometrial stromal cells using quantitative competitive po…

Adultendocrine systemmedicine.medical_specialtyStromal cellmedicine.drug_classmedicine.medical_treatmentInterleukin-1betaGonadotropin-releasing hormoneBiologyEndometriumGonadotropin-Releasing HormoneEndometriumInternal medicinemedicineHumansEmbryo ImplantationRNA MessengerBlastocystProtein PrecursorsReceptorObstetrics and GynecologyInterleukinReceptor antagonistInterleukin 1 Receptor Antagonist ProteinEndocrinologymedicine.anatomical_structureCytokineFemaleStromal Cellshormones hormone substitutes and hormone antagonistsJournal of Obstetrics and Gynaecology Research
researchProduct

High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist.

2011

High daily doses of gonadotrophin-releasing hormone (GnRH) antagonists during the follicular phase of ovarian stimulation were associated with low implantation rates. To test if this occurred because of profound pituitary suppression, the pituitary response was suppressed with a high-dose GnRH antagonist and recombinant LH (rLH) was added back to correct the implantation rate. An open-label, randomized, controlled, prospective clinical study in 60 patients undergoing IVF was performed. GnRH antagonist was initiated on day 6 of stimulation (2 mg/day) together with 375 IU rLH, and maintained until the day of HCG administration. Controls received 0.25 mg/day GnRH antagonist. Fluctuating LH con…

Adultendocrine systemmedicine.medical_specialtymedicine.medical_treatmentStimulationlaw.inventionGonadotropin-Releasing HormoneOvulation InductionlawInternal medicineFollicular phaseMedicineHumansProspective StudiesAdverse effectProspective cohort studyDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyLuteinizing HormoneRecombinant ProteinsDose–response relationshipEndocrinologyReproductive MedicineRecombinant DNAOvulation inductionFemalebusinesshormones hormone substitutes and hormone antagonistsDevelopmental BiologyHormoneReproductive biomedicine online
researchProduct

Early pregnancy loss in women stimulated with gonadotropin-releasing hormone antagonist protocols according to oral contraceptive pill pretreatment.

2007

Objective To evaluate and compare the risk of early pregnancy loss in patients stimulated with GnRH antagonist protocols according to oral contraceptive pill (OCP) pretreatment. Design Retrospective case–control study. Setting Instituto Valenciano de Infertilidad. University of Valencia. Spain. Patient(s) One thousand five hundred thirty-nine patients, aged Intervention(s) Reproductive outcome was compared based on the application (or not) of OCP pretreatment: 944 women were included in the OCP group and 595 in the non-OCP group. The Student's t test was used for statistics. Main Outcome Measure(s) Pregnancy, biochemical pregnancy, ectopic pregnancy, early clinical pregnancy loss, early pre…

Adultmedicine.medical_specialtyOral contraceptive pillPregnancy Ratemedicine.drug_classEarly Pregnancy LossGonadotropin-releasing hormone antagonistMiscarriageGonadotropin-Releasing HormonePregnancymedicineHumansRetrospective StudiesGynecologyPregnancyEctopic pregnancybusiness.industryObstetrics and Gynecologymedicine.diseasePregnancy rateReproductive MedicinePillCase-Control StudiesEmbryo LossFemalebusinessContraceptives OralFertility and sterility
researchProduct

Cycle scheduling for in vitro fertilization with oral contraceptive pills versus oral estradiol valerate: a randomized, controlled trial

2013

Abstract Background Both oral contraceptive pills (OCPs) and estradiol (E2) valerate have been used to schedule gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles and, consequently, laboratory activities. However, there are no studies comparing treatment outcomes directly between these two pretreatment methods. This randomized controlled trial was aimed at finding differences in ongoing pregnancy rates between GnRH antagonist IVF cycles scheduled with OCPs or E2 valerate. Methods Between January and May 2012, one hundred consecutive patients (nonobese, regularly cycling women 18–38 years with normal day 3 hormone levels and <3 previous IVF/ICSI attempts)…

Adultmedicine.medical_specialtyPregnancy Ratemedia_common.quotation_subjectPopulationPhysiologyFertilization in VitroCycle schedulingReproductive technologyGonadotropin-releasing hormoneValerateContraceptives Oral Hormonallaw.inventionGonadotropin-Releasing HormoneEndocrinologyRandomized controlled trialPregnancylawInternal medicineGnRH antagonistHumansMedicineeducationMenstrual CycleMenstrual cyclemedia_commonchemistry.chemical_classificationeducation.field_of_studyEstradiolOral contraceptivesbusiness.industryResearchEstradiol valerateEstrogen pretreatmentObstetrics and GynecologyPregnancy rateEndocrinologychemistryReproductive MedicineIVFFemalebusinessmedicine.drugDevelopmental BiologyReproductive Biology and Endocrinology
researchProduct

Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 400…

2010

background: The influence of elevated serum progesterone levels during in vitro fertilization/intracytoplasmic sperm injection (IVF/ ICSI) cycles on pregnancy rates is a matter of continued debate among fertility clinicians. Efforts to resolve this question have been impeded by the various assays used to measure progesterone and the different, arbitrary threshold values for defining ‘high’ progesterone levels. methods: A non-interventional, retrospective, observational, single-centre cohort study evaluated the relationship between serum progesterone levels on the day of human chorionic gonadotrophin (hCG) administration and the ongoing pregnancy rate in 4032 patients undergoing IVF/ICSI cyc…

Adultmedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedia_common.quotation_subjectmedicine.medical_treatmentFertilityStimulationFertilization in VitroGonadotropin-releasing hormoneBiologyChorionic GonadotropinIntracytoplasmic sperm injectionCohort StudiesGonadotropin-Releasing HormoneAndrologyOvulation InductionPregnancyInternal medicinemedicineHumansProgesteroneRetrospective Studiesmedia_commonPregnancyIn vitro fertilisationbusiness.industryRehabilitationObstetrics and GynecologyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseConfidence intervalPregnancy rateEndocrinologyReproductive MedicineRegression AnalysisReproductive Control AgentsGestationFemaleOvulation inductionFollicle Stimulating HormoneGonadotropinbusinesshormones hormone substitutes and hormone antagonistsHormoneHuman Reproduction
researchProduct

Characteristics of urinary luteinizing hormone (LH) during the induction of LH surges of different magnitude in blood

1995

Urinary luteinizing hormone (LH) testing has been proposed as a reliable method for the prediction of ovulation but its accuracy has been challenged by some studies. To check how accurately the oscillations of urinary LH reflected the plasma changes, surges of LH of different magnitude and duration were artificially induced in plasma and the hormone was measured simultaneously in urine. Post-menopausal women (n = 16) were stimulated during 1 week with a combination of transdermal oestradiol (400 micrograms) and i.m. progesterone (25 mg on day 4, 50 mg on day 5) to obtain an LH discharge comparable with the pre-ovulatory LH peak. A short and moderate peak of LH was induced by the i.v. inject…

Adultmedicine.medical_specialtyTime Factorsmedicine.drug_classmedia_common.quotation_subjectRadioimmunoassayGonadotropin-releasing hormoneUrineBuserelinSensitivity and SpecificityGonadotropin-Releasing HormoneAndrologyInternal medicinemedicineHumansOvulationProgesteronemedia_commonOvulation DetectionEstradiolChemistryEstrogen Replacement TherapyRehabilitationReproducibility of ResultsObstetrics and GynecologyLuteinizing HormoneMiddle Agedmedicine.diseaseBuserelinMenopauseEndocrinologyReproductive MedicineFemaleMenopauseGonadotropinLuteinizing hormonemedicine.drugHormoneHuman Reproduction
researchProduct

Mixed methods analysis of Health-Related Quality of Life in ambulant individuals affected with RYR1-related myopathies pre-post-N-acetylcysteine ther…

2020

Purpose: To characterize Health-Related Quality of Life (HRQoL) in ambulant individuals with RYR1-RM and to determine if a qualitative PRO tool (subjective self-assessment) complements PROMIS and Neuro-QoL scales to detect changes in HRQoL in ambulant individuals with RYR1-RM post N-acetylcysteine (NAC) treatment. Methods: The study used a mixed methods research (MMR) design applying methodological triangulation. Qualitative data were collected via semi-structured interviews using open-ended questions. Quantitative data were gathered through PROMIS and Neuro-QoL instruments. Additionally, qualitative data were transformed into quantitative data for subjective self-assessment and frequency a…

Adultmedicine.medical_specialtyWeaknessHealth StatusQualitative propertyArticleMuscular DiseasesQuality of lifeAdaptation PsychologicalmedicineHumansFatigueHealth related quality of lifeEsportsbusiness.industryPublic healthMultimethodologyPublic Health Environmental and Occupational HealthRyanodine Receptor Calcium Release ChannelAcetylcysteineClinical trialQuality of LifeFemaleEducació físicamedicine.symptombusinessNatural history studyClinical psychology
researchProduct

Benefits of a self-myofascial release program on health-related quality of life in people with fibromyalgia: a randomized controlled trial

2017

BACKGROUND Fibromyalgia (FM) is a disease with symptoms that significantly limit the life of affected patients. Earlier studies have shown that the application of self-myofascial release provides benefits in variables such as fatigue, range of motion (ROM) or perceived muscle pain in a healthy population. Despite this, the self-myofascial release technique has not yet been used in people with FM. This study aimed to find out the benefits of applying a self-myofascial release program on health-related quality of life in people with FM. METHODS Sixty-six participants with FM were randomized into two groups, intervention (N.=33) and control (N.=33). The intervention group (IG) participated in …

Adultmusculoskeletal diseasesmedicine.medical_specialtyFibromyalgiaPhysical Therapy Sports Therapy and Rehabilitationlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialQuality of lifelawFibromyalgiaHumansPain ManagementMedicineOrthopedics and Sports MedicineRange of Motion ArticularFatigueDepression (differential diagnoses)MassageHealth related quality of lifeAnalysis of Variancebusiness.industry030229 sport sciencesmedicine.diseaseDirectly Observed TherapyMyofascial releaseSelf CareQuality of LifePhysical therapyFemaleSelf ReportAnalysis of variancebusinessRange of motion030217 neurology & neurosurgeryThe Journal of Sports Medicine and Physical Fitness
researchProduct

Developmental Changes and Daily Rhythm in Melatonin-Induced Inhibition of 3′,5′-Cyclic AMP Accumulation in the Rat Pituitary

1990

Melatonin's transduction mechanisms were investigated using in vitro cultured anterior hemipituitaries. Melatonin inhibited cAMP and 3',5'-cyclic GMP accumulation in neonatal rat anterior pituitary stimulated with LHRH. Maximal inhibitory effect was reached within 25 min and persisted for at least 20 min. Inhibition of cAMP accumulation is specific for melatonin because its analogs N-acetylserotonin and 5-methoxytryptamine are 1000 times less potent. Melatonin effect is age- and time-dependent. Marked inhibition was observed in 5-, 10-, and 14-day-old rats but not in 29-day-old ones. Melatonin was significantly more potent when applied at the end of the light period as compared with the fir…

Agingendocrine systemmedicine.medical_specialtyPituitary glandTime FactorsGonadotropin-releasing hormoneIn Vitro TechniquesBiologyGonadotropin-Releasing HormoneMelatoninEndocrinologyAnterior pituitaryInternal medicineCyclic AMPmedicineAnimalsCircadian rhythmCyclic GMPMelatoninDose-Response Relationship DrugRats Inbred StrainsCircadian RhythmRatsDose–response relationshipEndocrinologymedicine.anatomical_structurePituitary GlandSecond messenger systemhormones hormone substitutes and hormone antagonistsEndocrine glandmedicine.drugEndocrinology
researchProduct

GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessor-blind study.

2009

The use of gonadotrophin-releasing hormone (GnRH) agonists for triggering ovulation remains controversial. The primary objective of this study was to evaluate the incidence of ovarian hyperstimulation syndrome (OHSS) following GnRH agonist versus recombinant human chorionic gonadotrophin (HCG) as methods for triggering ovulation. A second aim was to compare the clinical outcome and embryo quality according to the two procedures. The cycle characteristics of 100 oocyte donors undergoing ovarian stimulation and IVF outcomes of their 100 oocyte recipients were analysed. Donors were prospectively randomized into two groups on the last day of ovarian stimulation: Group I received a single bolus …

AgonistAdultendocrine systemmedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentmedia_common.quotation_subjectOvarian hyperstimulation syndromeFertilization in VitroChorionic GonadotropinAndrologyGonadotropin-Releasing HormoneOvarian Hyperstimulation SyndromeOvulation InductionPregnancymedicineHumansOvulationmedia_commonGynecologyPregnancyIn vitro fertilisationTriptorelin PamoateOocyte Donationbusiness.industryObstetrics and GynecologyOocytemedicine.diseaseTriptorelinRecombinant Proteinsmedicine.anatomical_structureTreatment OutcomeReproductive MedicineFemalebusinesshormones hormone substitutes and hormone antagonistsEmbryo qualityDevelopmental Biologymedicine.drugReproductive biomedicine online
researchProduct